Inadequate bowel preparation compromises colonoscopy quality and diagnostic accuracy, and cirrhosis is a recognized independent predictor of poor bowel cleansing. However, no bowel preparation regimen has been prospectively validated or specifically tailored for cirrhotic patients.
This multicenter, prospective, randomized, single-blind controlled clinical trial will evaluate whether the addition of adjunctive measures as an intensified bowel preparation protocol improves bowel cleansing quality in adult patients with cirrhosis undergoing elective outpatient colonoscopy.
Participants will be randomized 1:1 to receive either a standard bowel preparation protocol, consisting of a 2-litre split-dose polyethylene glycol (PEG) regimen combined with a one-day low-residue diet and clear liquids the afternoon before the procedure (control), or the same split-dose regimen with the assigned adjunctive measures: 15 mg bisacodyl, a 3-day low-residue diet, and clear liquids the day before colonoscopy (intervention).
The primary outcome is the proportion of patients achieving adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) total score ≥6 with no individual segment score <2. Secondary outcomes include polyp, adenoma, advanced adenoma and colorectal cancer detection rates, caecal intubation rate, patient compliance, tolerability, and adverse events. Pre-specified subgroup analyses will evaluate the influence of etiology and severity of cirrhosis and portal hypertension complications.
By addressing a critical and unmet clinical need, this trial aims to generate high-quality evidence to optimize bowel preparation strategies in patients with cirrhosis, improve colonoscopy quality, and ultimately enhance colorectal cancer screening outcomes in this vulnerable population.

Start Date01 Aug 2026

Sponsor / Collaborator

Hospital do Divino Espírito Santo de Ponta Delgada EPE

NCT07351357

/ Not yet recruitingPhase 4IIT

Multi-Centre Pragmatic Randomized Controlled Trial of Bowel Preparation Before Peritoneal Dialysis Catheter Insertion

Doctors need to insert catheter for patients who are going to have peritoneal dialysis. These peritoneal catheters can be obstructed or blocked afterward. The chance of not having smooth flow can be up to 12 and 31%. So far, constipation is one of the proposed reasons. Therefore, the study is aimed to investigate whether the preventive use of laxative before the surgery can help better improve the function of the catheter and hence better flow.

Start Date12 Jan 2026

Sponsor / Collaborator

The Chinese University of Hong Kong

PACTR202512709170316

/ SuspendedNot ApplicableIIT

Efficacy of bisacodyl suppository versus standard care in enhancing early recovery post cesarean section: A randomised controlled trial at Irrua Specialist Teaching Hospital, Irrua

Start Date04 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Bisacodyl

100 Translational Medicine associated with Bisacodyl

100 Patents (Medical) associated with Bisacodyl

815

Literatures (Medical) associated with Bisacodyl

01 Jul 2026·OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Investigating Immune Microenvironment of Inflammatory Bowel Disease and the Mitochondrial Metabolism-Related Molecular Mechanisms: Combining a Multiomics Approach and Experimental Validation

Article

Author: Li, Hao ; Wu, Qingping ; Wang, Jian ; Wu, Xichuan

Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal disease, the pathogenesis of which has not been fully elucidated. Increasing evidence suggests that the disorder of mitochondrial metabolism is closely related to the pathogenesis of IBD, but its specific regulatory network and key genes remain to be further investigated. IBD-related transcriptome datasets (GSE3365 and GSE75214) and single-cell sequencing dataset (GSE134809) were obtained from the Gene Expression Omnibus database. Differentially expressed genes and hub genes were identified through differential expression analysis and weighted gene co-expression network analysis, and candidate genes were obtained by intersecting these with mitochondrial metabolism-related genes, followed by functional enrichment analysis. Machine learning algorithms were used to screen key genes and construct risk prediction models. Additionally, analysis of GSE134809 single-cell data identified characteristic cell types and expression distribution of key genes in IBD and explored communication between different cell types. Furthermore, immune cell infiltration, competitive endogenous RNA (ceRNA) network, and transcription factor prediction were performed. Finally, the diagnostic performance of key genes was validated in GSE75214 and reverse transcription–quantitative polymerase chain reaction. Two key genes, mitochondrial ribosomal protein L35 ( MRPL35 ) and MRPL39 , were identified, which were downregulated in IBD, and had good diagnostic potential. Single-cell analysis revealed that key genes were predominantly highly expressed in mononuclear phagocyte (MNP) cells. MNP cells communicated with other cells through receptor ligands including MIF-(CD74 + CXCR4), MDK-SDC1, and ITGB2-ICAM2, which are complexly related to mitochondrial metabolism. With the progression of IBD, infiltration levels of resting natural killer cells, naive B cells, M2 macrophages, and naive CD4 T cells decreased, and correlations between different cells continuously changed. A ceRNA network centered on XIST, hsa-miR-103a-3p, and MRPL35 was constructed. Additionally, therapeutic drugs targeting key genes were predicted, including cimetidine, eugenol, chlortetracycline, vincristine, irinotecan, bisacodyl, and sulpiride, with molecular docking validating high affinity between these drugs and key targets. This study constructed a multiomics integrated analysis strategy and identified MRPL35 and MRPL39 as potential markers and therapeutic targets, providing new insights for the diagnosis and treatment of IBD.

04 May 2026·Expert Opinion On Drug Safety

Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases

Article

Author: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi

BACKGROUND:

Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).

RESEARCH DESIGN AND METHODS:

We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.

RESULTS:

We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.

CONCLUSION:

Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.

01 May 2026·NEUROGASTROENTEROLOGY AND MOTILITY

Effect of Linaclotide on Colonic Motility Assessed With Intraluminal Colonic High‐Resolution Manometry in Healthy Subjects. An Acute, Open Label, Randomized, Crossover, Reader‐Blinded Study

Article

Author: Ingrid Demedts ; Silvia Cocca ; Riccardo Morganti ; Jan Tack ; Maura Corsetti ; Christian Lambiase ; Eveline Deloose ; Giuseppe Pagliaro

ABSTRACT:

Background:

Polyethilenglicole (PEG), bisacodyl, prucalopride, and linaclotide were demonstrated to be superior to placebo for the treatment of chronic constipation. In a recent study, we reported the actions of PEG, bisacodyl, and prucalopride on colonic motor patterns. The aim of the present study was to evaluate the effect of linaclotide as compared to placebo on colonic motility assessed with high‐resolution manometry (HRM).

Methods:

In 10 volunteers (30.3 ± 10.6 years), two colonic HRM studies (40 solid‐state sensors, 2.5 cm spaced) were performed at least 10 days apart. After 90 min of basal recording, linaclotide 290 μg or placebo was administered orally in double‐blind, randomized, cross‐over fashion, and the recording continued for 180 min before and after a standardized meal. Colonic motility index (MI) of the right, left colon, and rectum, expressed as a ratio of the baseline value, was compared between treatments by means of a mixed model analysis. The number of high‐amplitude propagated sequences, of long‐distance propagating sequences, and of pan‐colonic pressurizations was compared between treatments.

Results:

Linaclotide induced more long‐distance propagating sequences than placebo (34.9 ± 41.2 vs. 3.0 ± 5.2, p = 0.026), especially during the meal and post‐meal phases of the recording. The total number of pancolonic pressurizations did not differ between treatments. However, a significant increase in the mean number of pre‐prandial pancolonic pressurizations was observed following linaclotide administration ( p = 0.043). No treatment effect was found on the change in colonic MI from the baseline in any region of the colon.

Conclusions:

In healthy controls, acute administration of linaclotide increases the total number of long‐distance propagating sequences and the pre‐prandial pancolonic pressurizations.

News (Medical) associated with Bisacodyl

07 Jul 2026

·www.opella.com

Press Release. Experts call for earlier recognition of fatty liver disease in people living with obesity.

Deep dive. Brussels, 7 July 2026 – At the Economics of Obesity and Metabolic Health Summit - hosted by Economist Enterprise and held on June 10 in Brussels with support from multiple organizations, including Opella and its liver brand Essentiale - healthcare experts, policymakers and public health leaders called for stronger policy action to address the growing burden of obesity and its co-morbidities. Particular attention was given to steatotic (“fatty”) liver disease as an often-overlooked consequence, with Prof. Jeffrey Lazarus (ISGlobal) and Prof. Norbert Stefan (Eberhard Karls University of Tübingen) highlighting the urgent need to elevate its visibility in public health agendas. They emphasized that improving awareness and earlier identification of individuals at increased metabolic risk are critical to enabling timely intervention and reducing long-term health system impact. Obesity is one of the fastest-growing public health challenges worldwide, with the global economic impact of obesity and metabolic disorders projected to exceed $4 trillion annually by 20351. Fatty liver disease is closely linked to obesity and impaired metabolic health, affecting approximately 70% to 80% of people living with obesity2. As obesity rates continue to increase, experts noted that the fatty liver is becoming more prevalent and is now recognized alongside cardiovascular disease and type 2 diabetes as a major obesity-related health concern. Key insights from the discussion: Prof. Norbert Stefan, Professor of Clinical and Experimental Diabetology at the University of Tübingen, highlighted the close relationship between obesity and fatty liver disease. He explained that fatty liver can be an important marker of impaired metabolic health and help identify individuals who may be more likely to develop obesity-related complications. Kwasi Boahene, Director of Health Systems at PharmAccess, emphasized that prevention is most effective when people have access to routine health checks, screening and follow-up care that enable earlier detection of metabolic health risks. Manuela Ripa, Member of the European Parliament, highlighted the need for stronger prevention policies and healthier food environments, stressing that investing in prevention can improve health outcomes while reducing long-term healthcare costs. Sohail Munshi, Joint Chief Medical Officer at Manchester University NHS Foundation Trust, emphasized the value of embedding prevention into routine healthcare interactions to help identify obesity-related risks earlier and support timely intervention. A common theme throughout the discussion was the need to improve awareness of fatty liver disease and its connection to obesity and metabolic health. Prof. Norbert Stefan. Professor of Clinical and Experimental Diabetology at the University of Tübingen. Not all people living with obesity face the same risk of developing obesity-related complications3. As healthcare systems face increasing pressure, it is becoming more important to identify those individuals at highest risk and intervene earlier. Fatty liver can be an important indicator of increased metabolic health risk, helping people and healthcare professionals recognize potential problems before more serious conditions develop. We have identified a fatty liver as the key characteristic that distinguishes people with healthy obesity from those with unhealthy obesity. These findings have also led to the recognition that, in addition to cardiovascular disease and type 2 diabetes, fatty liver disease is now also considered a condition for which the costs should be covered by the healthcare system. The discussion reinforced the importance of helping people better understand the links between obesity, metabolic health and fatty liver disease. Experts agreed that increasing awareness and recognising risk factors earlier could support more proactive health management and contribute to healthier populations in the years ahead. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet. Find out more about our mission at www.opella.com. Prof. Norbert Stefan. N.S. has received research support and materials from Opella to conduct a study in people with fatty liver disease and to attend the Economics of Obesity and Metabolic Health Summit; fees for consultancy and scientific talks from Allergan, AstraZeneca, Boehringer Ingelheim, Gilead, Genkyotex, GSK, Intercept Pharma, Lilly, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Opella and Pfizer; and has received research support from AstraZeneca, Boehringer Ingelheim, DSM Nutritional Products and Roche Diagnostics; and serves as coleader in the German Diabetes Association Study group MASLD. Press contacts. Philippa Carnohan. philippa.carnohan@opella.com. +33 6 31 14 82 36. All trademarks mentioned in this press release are the property of Opella. pdf version.

15 Jun 2026

·www.opella.com

Press Release. New Report Identifies Major Opportunity for UK Pharmacies to Advance Men’s Health.

Deep dive. UK, 15 June 2026 – Opella. While nine out of ten men surveyed (92%1) use their local pharmacy, almost three-quarters (74%2) of them leave without ever discussing their health with a pharmacist, a new report has revealed. This disconnect highlights a significant opportunity to catch illnesses earlier and alleviate pressure on the NHS. The report, "An Unfilled Prescription," published by the Men’s Health Forum and supported by global consumer health leader Opella, highlights a critical opportunity to convert men's regular presence in pharmacies into greater engagement with preventative health services. With UK men’s life expectancy four years shorter than women's, and over a third dying before their 75th birthday, the findings underline the valuable role the pharmacy sector can play as part of a wider effort to improve men’s health. The research identified the main barriers preventing men from living healthier lives, which, according to the men surveyed, include: Discomfort discussing health issues in a public retail space (22%3). A perception that seeking help is a sign of weakness (33%). A common tendency to delay seeking medical advice (36%). This silence, however, can have serious consequences. Over half of the men surveyed (57%4) reported that failing to seek advice led to negative impacts on their lives, including missed work (15%) and strained personal relationships (12%). Jim Pollard, Men’s Health Forum. With the UK Government rightly hoping to leverage pharmacies to relieve pressure on the NHS, this report is a clear call to action. We are committed to ensuring all men can live healthier, longer lives, and the key message for men is that pharmacy is for you. It is a far better source of health advice and information than, for example, AI, which simply cannot be recommended. By addressing the specific barriers preventing men from seeking advice, we can unlock the potential of pharmacies to become the front door to the health system for them. In response to the findings, the Men’s Health Forum has developed a practical five-step plan to help pharmacies better engage men and transform their stores into trusted health hubs. The plan was developed with feedback from pharmacists, nearly all of whom reported facing barriers to engaging male customers. The report calls on pharmacies to: 1. Create a Welcoming Space. Designate a clearly advertised private consulting room to ensure confidentiality. 2. Appoint a Champion. Nominate a 'Men’s Health Champion' trained in discussing men's health issues. 3. Offer Dedicated Services. Introduce dedicated services like 'men's health MOTs' and other tailored check-ups. 4. Improve Access & Guarantee Privacy. Review opening hours and implement online booking systems to offer flexibility and discretion. 5. Engage the Community Proactively. Actively reach out to men in the local community rather than waiting for them to ask for help. Nick Linton, UK Country Head, Opella. Community pharmacies are the frontline of our health service, and we are committed to supporting them. We welcome these recommendations, which provide clear, actionable guidance. Ensuring pharmacy meets its full potential will require a collaborative effort across government, regulators, and companies like Opella, and we are ready to play our par. The report found that men are willing to engage if the environment is right. Around a quarter of men surveyed said they would be more likely to talk to a pharmacist if they knew the conversation was private (24%) and that they could be referred to the NHS if needed (26%). Jim Pollard at Men’s Health Forum, conclude: It is vital that we get this right. We stand ready to work with pharmacies to make sure this opportunity isn’t missed. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet. Find out more about our mission at www.opella.com About Men's Health Forum. The Men's Health Forum's mission is to improve the health of men and boys in England, Wales and Scotland. To this end, we carry out research, raise awareness, work to change health policy, share and encourage the latest good practice, work with other charities and provide health information and advice to men through our website, training, Men's Health Week and our Man Manuals. Find out more at https://www.menshealthforum.org.uk. Press Contacts. Charlotte Messer. Charlotte.Messer@opella.com. +447928700277. Laura Webster. Laura.Webster@opella.com. +447740935106. All trademarks mentioned in this press release are the property of Opella. Methodology: The research was conducted by Censuswide, among a sample of 1675 respondents aged 18-65. The data was collected between 24.10.2025 - 27.10.2025. Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council. pdf version.

09 Jun 2026

·www.opella.com

Press Release. Opella expands global access to ED treatment with non-prescription approval of Cialis® in Japan.

Deep dive. Paris, June 9, 2026. Opella announces the non-prescription approval of Cialis® in Japan, a significant milestone that facilitates access to erectile dysfunction (ED) treatment for millions of men1. This follows the recent successful switch of Cialis® to an over-the-counter (OTC) medicine in Norway and the UK, reinforcing Opella's commitment to empowering consumers with trusted self-care solutions globally. ED is a common yet often under-discussed condition, with an estimated 322 million men2 living with the condition globally. In Japan alone, approximately 1 in 2 men are living with ED. Beyond its impact on sexual health, clinical research increasingly identifies ED as a hallmark and potential early warning sign of underlying cardiovascular disease3. The transition of Cialis® to an OTC product aims to provide a safe and reliable option for men, helping to combat the risks associated with purchasing counterfeit or unauthorized treatments online, by bringing patients back into the regulated healthcare system. Recent global research4 across six countries highlights a critical gap in understanding the condition. While 70-80% of men in the U.S. and Sweden understand the medical definition of ED, awareness is significantly lower in other markets. Yet, the desire for solutions is universal, with 90% of people globally viewing sexual wellbeing as vital to overall happiness. By expanding OTC access, Opella aims to bridge this education gap, break down societal stigmas, and empower men to reclaim their wellbeing. Dr Josephine Fubara, Chief Science Officer at Opella: This approval for non-prescription status in Japan represents more than just a local milestone, it is a crucial step forward in our broader mission to make healthcare more accessible on a global scale. Following the successful switch in Norway and the UK, we are committed to bringing this trusted treatment to men by expanding over-the-counter access. By shifting proven treatments from prescription to pharmacy shelves, we are fundamentally changing how men access care, putting science-backed solutions directly into their hands, safely guided by pharmacist expertise. According to a study by the Global Self-Care Federation (GSCF), self-care practices currently save global healthcare systems nearly $120 billion annually and free up 1.8 billion physician hours5. By moving proven, well-established treatments from the clinic to pharmacy shelves, it can alleviate the strain on primary care providers, while enabling individuals to take faster, more autonomous action over their health. After 20 years of trusted use as a prescription ED treatment in Japan and over 100 countries globally, Cialis® will soon be available over-the-counter. The non-prescription approval was granted to SSP Co., Ltd., an Opella company, with launch planning currently underway to bring the medicine to shelves in the coming months. Classified as a 'Pharmacist-Intervention Required Medicine,' the switch ensures that men will receive the necessary guidance and information directly from a healthcare professional at the point of purchase. Alberto Hernandez, Chief Growth Officer at Opella: Rx-to-OTC switches are an important pillar of Opella’s growth strategy and by successfully launching Cialis without a prescription in markets like Japan and Norway, we demonstrate our ability to unlock new categories and bring trusted self-care brands directly to the consumers who need it. For Opella, non-prescription switch is a strategic growth driver. Backed by rigorous safety and efficacy data submitted to national health authorities, well-targeted switches like those in the UK, Norway and Japan, advance Opella's commitment to simplifying healthcare and expanding access to trusted treatments. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet. Find out more about our mission at www.opella.com. Press contacts. Justine Rohée. justine.rohee@sanofi.com. +33 6 86 47 85 60. Natacha Kalasa. natacha.kalasa@sanofi.com. +33 6 72 16 64 61. Philippa Carnohan. philippa.carnohan@opella.com. +33 6 31 14 82 36. Cialis PR Office (Japan). cialis_pr@vectorinc.co.jp. +81 3-5572-6071. pdf version.

Drug Approval

100 Deals associated with Bisacodyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00245	Bisacodyl	A06AG02 A06AB02	DB09020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	-	Pfizer Inc.	01 Jan 1953

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Constipation - functional	Phase 3	Germany	Boehringer Ingelheim Pharma GmbH & Co., KG	09 Aug 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02977286 (CTgov)	Phase 4	Constipation	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Naloxegol Oral Tablet+Senna 217 Mg Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	yraxzqgfcg(ovkrhuofwy) = pbkpoyghzc tgyfsphbhv (jcmdcecwdq, 25) View more	-	16 Feb 2023
				Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	yraxzqgfcg(ovkrhuofwy) = fwxkxfzxup tgyfsphbhv (jcmdcecwdq, 25) View more
NCT02976805 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 3	-	196	PEG 2 liters the evening before and 2 liters the day of colonoscopy (PEG 2+2L+bisacodyl)	sfyocyeucu(ueianezcih) = oqvlxxsybf atwsglqaxb (ibftygizfl ) View more	-	01 Jun 2022
				4 liters and 2 liters (PEG 4+2L+bisacodyl)	sfyocyeucu(ueianezcih) = jbejzmxqrn atwsglqaxb (ibftygizfl ) View more
NCT02609607 (CTgov)	Phase 2	Fecal Incontinence \| Multiple Sclerosis \| Chronic constipation ... View more	11	Placebo (Placebo)	lwfppcjafn = gjgbhtecxp rqmbdqckdo (wojtzkkekz, rkjprxnuhk - mwiawvsdrk) View more	-	22 Jan 2020
				Bisacodyl (Bisacodyl)	lwfppcjafn = zrcgkbcgvz rqmbdqckdo (wojtzkkekz, wqegeihugy - ldefavkssq) View more
NCT02383758 (CTgov)	Not Applicable	Autism Spectrum Disorder \| Autistic Disorder \| Stool soiling	22	Glycerin Suppository+Bisacodyl suppository+Senna (Treatment Program)	hgqozycykd = lbxsclhfmn lduvkltzeq (dsgyilkgzw, crxfnkmmfo - ewldpzjjxy) View more	-	11 Jan 2018
				Glycerin Suppository+Bisacodyl suppository+Senna (Waitlist Control)	hgqozycykd = lkszzbtqcu lduvkltzeq (dsgyilkgzw, cezoxifdqb - dmrgiztemp) View more
NCT02481219 (CTgov)	Not Applicable	Colorectal Cancer	122	SUPREP oral sulfate solution+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen -Control)	xqjgfiuffy = zlrvwvifhk lbqdtlpieb (ciqahyqmhh, gohlzuuoac - uonqznhouu) View more	-	11 Jul 2016
				SUPREP oral sulfate solution with Gastrografin+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen-Test)	xqjgfiuffy = twrqzsvvnz lbqdtlpieb (ciqahyqmhh, czctggzrno - azqtptbaom) View more
NCT01917773 (CTgov)	Phase 4	Chronic constipation \| Constipation	13	octreotide (15 Minutes)	sfqzljzrmr(eufobiosia) = jyviaakqia hmjqhrqpyg (pwtzgdxdxw, wjfeebpszq - ssgazqhmxc) View more	-	21 Dec 2015
				octreotide (30 Minutes)	sfqzljzrmr(eufobiosia) = kaaqshwqnw hmjqhrqpyg (pwtzgdxdxw, xtaogovpcn - wvgjvbnwfd) View more
NCT01044212 (CTgov)	Not Applicable	Intestinal Diseases \| Enterocele	72	Polyethylene glycol+Dulcolax+Colace	hkrzjxxkti(tmbtruqifi) = ywdvhritqi oyzksywqet (azodbcvwud, 21) View more	-	21 Oct 2015
NCT01073943 \| NCT01073930 (SEE CLEAR I \| SEE CLEAR II, ECCO2014)	Phase 3	Intestinal preparation	-	P/MC Split-dose	zkixqyrzmu(xbraoquabd) = Both dosing regimens of P/MC were equally effective at bowel cleansing in all pts, regardless of age nhnhiajbmd (njgsyxhhbk ) View more	Positive	01 Feb 2014
				P/MC Day Before
NCT01063049 (CTgov)	Phase 4	Colonic Diseases	600	NuLytely (Nulytely)	uqoyonccqq(edfnitfimt) = vcajkkadze jkmedqbilv (gnyrhfhejc, 1.55) View more	-	18 Nov 2013
				Placebo+Miralax (Gatorade/Miralax + Placebo)	uqoyonccqq(edfnitfimt) = coasdbvgrb jkmedqbilv (gnyrhfhejc, 1.28) View more
NCT00953017 (CTgov)	Phase 4	-	425	Amitiza (Miralax Plus Amitiza)	pvlgsjhutj(hzmvvntyxg) = qdjrlmnuel voiicwrsyu (nwamudofhy, mdqshezeis - ulfilbchyb) View more	-	30 Nov 2012
				Bisacodyl (Miralax Plus Dulcolax)	pvlgsjhutj(hzmvvntyxg) = kcbkljsayk voiicwrsyu (nwamudofhy, nriisbosab - qqzbpyolvv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis